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Background and Purpose  The Movement Disorder Society-Sponsored Revision of the Uni-
fied Parkinson’s Disease Rating Scale (MDS-UPDRS) is widely used for estimating the symp-
toms of Parkinson’s disease. Translation and validation of the MDS-UPDRS is necessary for 
non-English speaking countries and regions. The aim of this study was to validate the Korean 
version of the MDS-UPDRS. 
Methods  Altogether, 362 patients in 19 centers were recruited for this study. We translated 
the MDS-UPDRS to Korean using the translation-back translation method and cognitive pre-
testing. We performed both confirmatory and exploratory factor analyses to validate the scale. 
We calculated the comparative fit index (CFI) for confirmatory factor analysis, and used un-
weighted least squares for exploratory factor analysis.
Results  The CFI was higher than 0.90 for all parts of the scale. Exploratory factor analysis 
also showed that the Korean MDS-UPDRS has the same number of factors in each part as the 
English version.
Conclusions  The Korean MDS-UPDRS has the same overall structure as the English MDS-
UPDRS. Our translated scale can be designated as the official Korean MDS-UPDRS.
Key Words   Parkinson’s diease, Movement Disorder Society Sponsored Revision of the 
Unified Parkinson’s Disease Rating Scale, validation, rating scale.
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INTRODUCTION
Parkinson’s disease (PD) is characterized by various motor 
and nonmotor symptoms and is the second most common 
neurodegenerative disease. Estimating the severity of PD is 
challenging due to the heterogenic nature of its clinical pre-
sentation, which includes motor and nonmotor symptoms as 
well as motor complications. PD severity could only be assessed 
in interviews and using a clinical scale to evaluate the abili-
ties to perform simple tasks. The Unified Parkinson’s Disease 
Rating Scale (UPDRS) was introduced in the 1980s and has 
become the most commonly used clinical scale for estimat-
ing the motor and nonmotor symptoms of PD patients.1 In 
2001, a taskforce sponsored by the Movement Disorder So-
ciety (MDS) highlighted some limitations and strengths of 
the UPDRS.2 A new version of the UPDRS was proposed, 
with the revised scale called the Movement Disorder Society 
Sponsored Revision of the Unified Parkinson’s Disease Rat-
ing Scale (MDS-UPDRS).3 The MDS-UPDRS includes the 
strengths of the UPDRS and improves its many drawbacks, 
and shows acceptable validity and reliability.4 The MDS-UP-
DRS is currently the official clinical scale used to analyze symp-
toms of PD, and it has been widely used in research and clini-
cal settings. 
The MDS-UPDRS comprises four parts. Part I (nonmotor 
aspects of experiences of daily living) and part II (motor as-
pects of experiences of daily living) comprise questionnaires 
that should be completed by patients or caregivers, and so it 
is crucial that simple and common expressions are used in 
parts I and II to obtain accurate information. The use of eas-
ily understood expressions in part III (motor examination) 
and part IV (motor complications) of the MDS-UPDRS is also 
important for translation and validation purposes. These 
parts are used by general clinicians and movement experts 
for clinical and research purposes. 
The MDS-UPDRS has been translated and validated in 
many countries after considering language and culture dif-
ferences, including into language version for Italian, Chinese, 
Dutch, German, French, Hebrew, Japanese, and Korean. The 
Italian, Hebrew, and Japanese versions of the MDS-UPDRS 
have demonstrated validity and reliability.5-7 
The prevalence of PD among the older population above 
60 years is 1.4% in Korea, and this is increasing more rapidly 
than the crude prevalence rate.8 Public awareness of the roles 
of age and education level in the prevalence of PD in Korea is 
also increasing, and the demand for using the MDS-UPDRS 
is expected to increase.9 The present study aimed to validate 
the Korean version of the MDS-UPDRS using factor analyses. 
METHODS
Study design
This validation style had an observational, cross-sectional de-
sign. Translation of the MDS-UPDRS into Korean was per-
formed in three stages: 1) translation and back-translation, 
2) cognitive pretesting, and 3) large-scale validation testing. 
Stages 1 and 2 were performed by a task force comprising the 
Korean Movement Disorder Society in collaboration with 
the MDS. For stage 3, we enrolled 362 native-Korean-speak-
ing PD patients selected from 17 centers in Korea to perform 
both confirmatory factor analysis (CFA) and exploratory 
factor analysis (EFA) for the validation. We also evaluated the 
internal consistency to determine the reliability of the scale 
using Cronbach’s alpha coefficient. This study was approved 
by the Institutional Review Board at each center, and all par-
ticipants provided written informed consent (IRB no.: HY 
2014-02-002-008).
Stage 1: translation protocol 
We translated the original MDS-UPDRS into Korean using 
the translation–back-translation method. The two teams 
that independently performed translation and back-trans-
lation consisted of members of the Korean Movement Disor-
der Society. All members of the teams were experts in move-
ment disorders, and at least one investigator on each team 
was fluent in English. The translation team first translated 
the original MDS-UPDRS into Korean, and then the back-
translation team retranslated the Korean MDS-UPDRS into 
English. These translation and retranslation processes were 
performed blindly. After finishing the translation–retransla-
tion processes, the teams compared the Korean MDS-UPDRS 
with the original English version and corrected mismatches. 
Stage 2: cognitive pretesting 
Cognitive pretesting is a qualitative approach to assessing in-
strument usability (or ease of completion) in terms of task 
difficulty for both the examiner and respondent. This pretest-
ing method also assesses the interest, attention span, discom-
fort, and comprehension of the respondents.10 Ten PD patients 
and three raters were interviewed, and a scale from 1 point to 
6 points was used to rate the difficulty during cognitive pretest-
ing. When differences were observed between the back-trans-
lated Korean version and the original English version of the 
MDS-UPDRS, items and questions that were identified as po-
tentially difficult in the cognitive-testing section of the English 
version were selected for cognitive pretesting. Topics included 
in the cognitive pretesting were cognitive impairment, anxi-
ety, features of dopamine dysregulation syndrome, handwrit-
ing, freezing, hand movements, rising from a chair, postural 
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stability, time spent with dyskinesia, and functional impact of 
dyskinesia. 
Based on the results of the initial cognitive pretesting, ad-
ditional rounds of translation, back-translation, and cogni-
tive pretesting were required for the selected items. The final 
translation was considered to have been achieved when cog-
nitive pretesting was completed and no problems were noted. 
After pretesting, the all translators collaborated to correct it and 
adapt it to Korean culture. 
Stage 3: factor analyses and large-scale validation 
testing 
This study applied both CFA and EFA, with the analyses per-
formed using M-plus software (version 7). The unweighted 
least-squares (ULS) approach was used to estimate the min-
imum sum of the squared differences between the observed 
and estimated correlation matrices. We interpreted these fac-
tors used orthogonal Crawford-Ferguson (CF) varimax rota-
tion, which restricts the uncorrelated factors. The sample size 
for the translation study was determined based on five sub-
jects per item of the questionnaire being needed to perform 
the statistical analyses. Because the MDS-UPDRS contains 
65 items, a sample of at least 325 participants was required. 
This study had a nationwide multicenter design, and so based 
on an estimated maximum dropout rate of 20%, 390 was set 
as the target sample size. 
Any participant with missing values for any part of the 
MDS-UPDRS was excluded from the analysis of only that 
part, which meant that the sample size could vary between dif-
ferent parts of the scale. The investigators obtained approval 
from all participants to collect their data. Anonymized data 
that did not include patient names or medical record num-
bers were transferred to the analysis team via a secure website. 
Primary analysis
The primary analysis of the Korean MDS-UPDRS data was 
performed using a CFA to determine if the factor structure for 
the English MDS-UPDRS could be confirmed based on the 
data collected using the Korean translation. This was the pri-
mary interest. The CFA was conducted separately for parts I 
and IV of the MDS-UPDRS, with the Korean data limited to 
factors defined by the English-language data. We evaluated 
the CFA results using the comparative fit index (CFI). Ac-
cording to the protocol, to establish a successful translated ver-
sion and to designate that as the official translated version of 
the MDS-UPDRS, the CFI values for parts I to IV of the trans-
lated MDS-UPDRS were required to be at least 0.90 when 
compared with the English version. We also investigated the 
root-mean-square error approximation (RMSEA) for the CFA. 
The mean and variance-adjusted weighted least-squares 
(WLSMV) estimator was used to confirm the model fit.
Secondary analysis
We conducted an EFA of the Korean version of the MDS-UP-
DRS (parts I–IV) to explore the underlying factor structure 
without the limitation of a prespecified factor structure. We 
produced a scree plot of the English version and used infor-
mation from it to choose the number of factors to retain for 
each part of the MDS-UPDRS. The subjective scree test uses 
a scatter plot of eigenvalues versus their ranks with regard to 
magnitude to extract as many factors as there are eigenvalues 
that decrease before the last large decrease like elbow shape 
occurs in the plot. An item was retained for a chosen factor 
if the factor loading for that item was at least 0.40. The inter-
pretation of the factors was assisted by using an orthogonal CF 
varimax rotation, which sets the factors to be uncorrelated.
The ULS estimator is the default used for factor analysis in 
M-plus. When the ULS estimator converges, it yields more ac-
curate parameter estimates and standard errors than when us-
ing the WLSMV estimator. However, the convergence rate is 
generally better for the WLSMV than the ULS estimator.11 If 
convergence does not occur, it is suggested that the maximum 
likelihood (ML) should be used because this method may 
converge when the ULS estimator does not. The ULS algo-
rithm did converge in the present study, but this was to an 
incorrect value (i.e., it explained more than 100% of the vari-
ance), and so the ML was used.
RESULTS
Cognitive pretesting
Ten PD patients and three raters were interviewed using the 
structured interview format that is typical used for cognitive 
pretesting. Cognitive pretesting produced acceptable results 
for most of the scale items. The overall cognitive pretesting 
score for all items was 5.5±1.3 (mean±standard deviation). 
However, two items had relatively low scores: dopamine dys-
regulation (4.7±1.1) and postural stability (5.1±0.3). The feed-
back from the responders indicated that the dopamine regu-
lation item had problems with privacy infringement, while 
the postural stability item had problems caused by long sen-
tences. After these two items were modified to make them 
easier to understand, no items were identified as problemat-
ic during the second round of testing. 
The modified version of the scale was approved by the 
MDS as the Official Working Draft of the Korean MDS-UP-
DRS that was administered to a larger group of PD patients 
for further testing. After cognitive pretesting, this translated 
Korean MDS-UPDRS was posted on the official MDS homep-
age and shared before large-scale validation was performed. 
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The Korean data set contained information obtained from 
390 native Korean-speaking PD patients who were examined 
using the MDS-UPDRS. The data from 28 of these 390 par-
ticipants were excluded due to incorrect or missing informa-
tion, and so finally 362 PD patients were enrolled. 
The demographic information of the participants (all of 
whom were Korean) is presented in Table 1. Table 2 presents 
the distributions of item responses provided by the Korean-
speaking and English-speaking groups.






Sex, male/female 150/212 554/322 <0.01*
Age, years 68.3±9.5 67.5±10.9 8.15 
Disease duration, years 6.1±4.0 8.3±6.7 5.10 
Education level, years 8.12±4.82
Hoehn and Yahr stage 2.23±8.99
MDS-UPDRS part III score 25.67±15.35
Data are n or mean±standard-deviation values.
*Chi-squred test.
MDS-UPDRS: Movement Disorder Society Sponsored Revision of the 
Unified Parkinson’s Disease Rating Scale.





n % n % n % n %
Part I
Cognitive impairment   Daytime sleepiness
0 428 48.86 159 43.9 0 212 24.20 177 48.9
1 256 29.22 129 35.6 1 216 24.66 96 26.5
2 121 13.81 48 13.3 2 364 41.55 70 19.3
3 53 6.05 23 6.4 3 59 6.74 15 4.1
4 17 1.94 2 0.6 4 16 1.83 4 1.1
999 1 0.11 1 0.3 999 9 1.03 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Hallucinations and psychosis   Pain and other sensations
0 687 78.42 291 80.4 0 303 34.59 170 47.0
1 89 10.16 42 11.6 1 289 32.99 109 30.1
2 51 5.82 19 5.3 2 130 14.84 59 16.3
3 35 4.00 8 2.2 3 106 12.10 24 6.6
4 13 1.48 2 0.6 4 39 4.45 0 0.0
999 1 0.11 0 0.0 999 9 1.03 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Depressed mood   Urinary problems
0 471 53.77 182 50.3 0 325 37.10 150 41.4
1 265 30.25 123 34.0 1 281 32.08 114 31.5
2 81 9.25 38 10.5 2 137 15.64 75 20.7
3 45 5.14 18 5.0 3 88 10.05 19 5.3
4 12 1.37 0 0.0 4 38 4.34 3 0.8
999 2 0.23 1 0.3 999 7 0.80 1 0.3
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Anxious mood   Constipation problems
0 413 47.15 183 50.6 0 362 43.84 128 35.4
1 307 35.05 123 34.0 1 287 32.76 111 30.7
2 96 10.96 43 11.9 2 119 13.58 75 20.7
3 41 4.68 12 3.3 3 70 7.99 46 12.7
4 17 1.94 1 0.3 4 9 1.03 2 0.6
999 2 0.23 0 0.0 999 7 0.80 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Apathy   Light headedness on standing
0 584 66.67 240 66.3 0 490 55.94 198 54.7
1 141 16.10 67 18.5 1 216 24.66 107 29.6
2 88 10.05 36 9.9 2 103 11.76 48 13.3
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n % n % n % n %
3 52 5.94 18 5.0 3 51 5.82 9 2.5
4 8 0.91 0 0.0 4 9 1.03 0 0.0
999 3 0.34 1 0.3 999 7 0.80 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Features of dopamine dysregulation syndrome   Fatigue
0 747 85.27 317 87.6   0 217 24.77 125 34.5
1 57 6.51 19 5.3   1 335 38.24 121 33.4
2 44 5.02 14 3.9   2 184 21.00 75 20.7
3 19 2.17 11 3.0   3 81 9.25 35 9.7
4 6 0.68 0 0.0   4 50 5.71 5 1.4
999 3 0.34 1 0.3   999 9 1.03 1 0.3
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Sleep problems            
0 280 31.96 141 39.0            
1 202 23.06 93 25.7            
2 207 23.63 88 24.3            
3 140 15.98 38 10.5            
4 40 4.57 1 0.3            
999 7 0.80 1 0.3            
Total 876 100.00 362 100.0            
Part II
Speech   Doing hobbies and other activities
0 252 28.77 151 41.7 0 227 25.91 141 39.0
1 236 26.94 126 34.8 1 289 32.99 99 27.4
2 233 26.60 55 15.2 2 185 21.12 59 16.3
3 126 14.38 30 8.3 3 81 9.25 43 11.9
4 22 2.51 0 0.0 4 84 9.59 20 5.5
999 7 0.80 0 0.0 999 10 1.14 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Saliva and drooling   Turning in bed
0 341 38.93 177 48.9 0 277 31.62 181 50.0
1 115 13.13 94 26.0 1 378 43.15 116 32.0
2 203 23.17 62 17.1 2 111 12.67 40 11.1
3 157 17.92 25 6.9 3 55 6.28 20 5.5
4 53 6.05 4 1.1 4 50 5.71 5 1.4
999 7 0.80 0 0.0 999 5 0.57 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Chewing and swallowing   Tremor
0 549 62.67 255 70.4 0 189 21.58 114 31.5
1 230 26.26 81 22.4 1 360 41.10 157 43.4
2 54 6.16 24 6.6 2 212 24.20 62 17.1
3 34 3.88 2 0.6 3 72 8.22 18 5.0
4 3 0.34 0 0.0 4 36 4.11 10 2.8
999 6 0.68 0 0.0 999 7 0.80 1 0.3
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Eating tasks   Getting out of bed
0 363 41.44 184 50.8 0 180 20.55 142 39.2
1 265 30.25 122 33.7 1 317 36.19 120 33.2
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n % n % n % n %
2 187 21.35 44 12.2 2 199 22.72 66 18.2
3 42 4.79 12 3.3 3 104 11.87 28 7.7
4 10 1.14 0 0.0 4 70 7.99 5 1.4
999 9 1.03 0 0.0 999 6 0.68 1 0.3
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Dressing   Walking and balance
0 220 25.11 151 41.7 0 184 21.00 123 34.0
1 322 36.76 149 41.2 1 336 38.36 147 40.6
2 211 24.09 40 11.1 2 105 11.99 58 16.0
3 76 8.68 21 5.8 3 172 19.63 24 6.6
4 42 4.79 0 0.0 4 74 8.45 10 2.8
999 5 0.57 1 0.3 999 5 0.57 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Hygiene   Freezing
0 342 39.04 184 50.8   0 453 51.71 236 65.2
1 367 41.89 117 32.3   1 182 20.78 72 19.9
2 88 10.05 46 12.7   2 89 10.16 37 10.2
3 33 3.77 14 3.9   3 90 10.27 10 2.8
4 38 4.34 1 0.3   4 56 6.39 7 1.9
999 8 0.91 0 0.0   999 6 0.68 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Handwriting            
0 161 18.38 101 27.9            
1 251 28.65 172 47.5            
2 222 25.34 66 18.2            
3 146 16.67 18 5.0            
4 87 9.93 5 1.4            
999 9 1.03 0 0.0            
Total 876 100.00 362 100.0            
Part III
Speech   Rising from a chair
0 189 21.58 111 30.7 0 422 48.17 220 60.8
1 379 43.26 180 49.7 1 245 27.97 94 26.0
2 213 24.32 67 18.5 2 78 8.90 28 7.7
3 69 7.88 4 1.1 3 71 8.11 10 2.8
4 22 2.51 0 0.0 4 55 6.28 10 2.8
999 4 0.46 0 0.0 999 5 0.57 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Facial expression   Gait
0 96 10.96 60 16.6 0 202 23.06 94 26.0
1 300 34.25 192 53.0 1 351 40.07 178 49.2
2 361 41.21 90 24.9 2 167 19.06 59 16.3
3 89 10.16 19 5.3 3 97 11.07 21 5.8
4 26 2.97 1 0.3 4 55 6.28 10 2.8
999 4 0.46 0 0.0 999 4 0.46 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Rigidity: neck   Freezing of gait
0 260 29.68 144 39.8 0 655 74.77 255 70.4
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n % n % n % n %
1 247 28.20 151 41.7 1 95 10.84 65 18.0
2 274 31.28 52 14.4 2 60 6.85 23 6.4
3 73 8.33 14 3.9 3 26 2.97 12 3.3
4 16 1.83 1 0.3 4 38 4.34 7 1.9
999 6 0.68 0 0.0 999 2 0.23 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Rigidity: RUE   Postural stability
0 176 20.09 100 27.6 0 422 48.17 201 55.5
1 282 32.19 178 49.2 1 157 17.92 74 20.4
2 342 39.04 76 21.0 2 60 6.85 40 11.1
3 69 7.88 8 2.2 3 149 17.01 40 11.1
4 6 0.68 0 0.0 4 86 9.82 7 1.9
999 1 0.11 0 0.0 999 2 0.23 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Rigidity: LUE   Posture
0 205 23.40 103 28.5 0 173 19.75 75 20.7
1 268 30.59 182 50.3 1 337 38.47 174 48.1
2 317 36.19 66 18.2 2 206 23.52 86 23.8
3 77 8.79 9 2.5 3 125 14.27 18 5.0
4 7 0.80 2 0.6 4 33 3.77 9 2.5
999 2 0.23 0 0.0 999 2 0.23 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Rigidity: RLE   Global spontaneity of movement
0 272 31.05 175 48.3   0 108 12.33 58 16.0
1 248 28.31 146 40.3   1 278 31.74 172 47.5
2 275 31.39 35 9.7   2 279 31.85 106 29.3
3 67 7.65 6 1.7   3 184 21.00 17 4.7
4 10 1.14 0 0.0   4 27 3.08 8 2.2
999 4 0.46 0 0.0   999 0 0.00 1 0.3
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Rigidity: LLE   Postural tremor: right hand
0 286 32.65 167 46.1   0 544 62.10 185 51.1
1 227 25.91 146 40.3   1 262 29.91 146 40.3
2 275 31.39 38 10.5   2 43 4.91 29 8.0
3 75 8.56 9 2.5   3 23 2.63 2 0.6
4 11 1.26 2 0.6   4 1 0.11 0 0.0
999 2 0.23 0 0.0   999 3 0.34 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Finger tapping: right hand Postural tremor: left hand
0 122 13.93 81 22.4   0 518 59.13 174 48.1
1 342 39.04 165 45.6   1 276 31.51 150 41.4
2 252 28.77 83 22.9   2 49 5.59 30 8.3
3 144 16.44 32 8.8   3 29 3.31 8 2.2
4 15 1.71 0 0.0   4 1 0.11 0 0.0
999 1 0.11 1 0.3   999 3 0.34 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Finger tapping: left hand Kinetic tremor: right hand
0 108 12.33 84 23.2   0 546 62.33 213 58.8
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n % n % n % n %
1 298 34.02 134 37.0   1 265 30.25 127 35.1
2 265 30.25 94 26.0   2 46 5.25 19 5.3
3 181 20.66 46 12.7   3 13 1.48 2 0.6
4 22 2.51 4 1.1   4 2 0.23 1 0.3
999 2 0.23 0 0.0   999 4 0.46 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Hand movements: right hand Kinetic tremor: left hand
0 187 21.35 122 33.7   0 493 56.28 200 55.3
1 346 39.50 169 46.7   1 293 33.45 133 36.7
2 231 26.37 54 14.9   2 72 8.22 25 6.9
3 98 11.19 16 4.4   3 14 1.60 3 0.8
4 12 1.37 0 0.0   4 0 0.00 1 0.3
999 2 0.23 1 0.3   999 4 0.46 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Hand movements: left hand Rest tremor amplitude: RUE
0 164 18.72 122 33.7   0 586 66.89 262 72.4
1 311 35.50 143 39.5   1 112 12.79 71 19.6
2 250 28.54 76 21.0   2 121 13.81 25 6.9
3 125 14.27 16 4.4   3 53 6.05 4 1.1
4 25 2.85 5 1.4   4 3 0.34 0 0.0
999 1 0.11 0 0.0   999 1 0.11 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Pronation–supination movements: right hand Rest tremor amplitude: LUE
0 199 22.72 111 30.7   0 603 68.84 242 66.9
1 335 38.24 185 51.1   1 120 13.70 69 19.1
2 216 24.66 57 15.8   2 99 11.30 44 12.2
3 107 12.21 9 2.5   3 45 5.14 7 1.9
4 17 1.94 0 0.0   4 5 0.57 0 0.0
999 2 0.23 0 0.0   999 4 0.46 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Pronation–supination movements: left hand Rest tremor amplitude: RLE
0 162 18.49 115 31.8   0 777 88.70 313 86.5
1 297 33.90 145 40.1   1 52 5.94 37 10.2
2 235 26.83 72 19.9   2 35 4.00 12 3.3
3 150 17.12 30 8.3   3 9 1.03 0 0.0
4 29 3.31 0 0.0   4 0 0.00 0 0.0
999 3 0.34 0 0.0   999 3 0.34 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Toe tapping: right foot Rest tremor amplitude: LLE
0 168 19.18 145 40.1   0 795 90.75 309 85.4
1 323 36.87 147 40.6   1 46 5.25 33 9.1
2 228 26.03 64 17.7   2 20 2.28 17 4.7
3 129 14.73 6 1.7   3 12 1.37 3 0.8
4 27 3.08 0 0.0   4 0 0.00 0 0.0
999 1 0.11 0 0.0   999 3 0.34 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Toe tapping: left foot Rest tremor amplitude: lip/jaw
0 154 17.58 138 38.1   0 780 89.04 318 87.9
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n % n % n % n %
1 251 28.65 117 32.3   1 63 7.19 38 10.5
2 268 30.59 85 23.5   2 18 2.05 6 1.7
3 154 17.58 20 5.5   3 13 1.48 0 0.0
4 46 5.25 2 0.6   4 1 0.11 0 0.0
999 3 0.34 0 0.0   999 1 0.11 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Leg agility: right leg Constancy of rest tremor
0 250 28.54 187 51.7   0 409 46.69 174 48.1
1 329 37.56 121 33.4   1 214 24.43 115 31.8
2 190 21.69 48 13.3   2 91 10.39 50 13.8
3 86 9.82 4 1.1   3 85 9.70 14 3.9
4 18 2.05 2 0.6   4 67 7.65 9 2.5
999 3 0.34 0 0.0   999 10 1.14 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
Leg agility: left leg          
0 216 24.66 173 47.8  
1 298 34.02 121 33.4  
2 213 24.32 54 14.9  
3 106 12.10 11 3.0  
4 38 4.34 3 0.8  
999 5 0.57 0 0.0  
Total 876 100.00 362 100.0  
Part IV
Time spent with dyskinesia Functional impact of fluctuations
0 563 64.27 248 68.5 0 433 49.43 264 72.9
1 173 19.75 53 14.6 1 165 18.84 35 9.7
2 87 9.93 36 9.9 2 81 9.25 35 9.7
3 27 3.08 18 5.0 3 119 13.58 22 6.1
4 17 1.94 7 1.9 4 63 7.19 6 1.7
999 9 1.03 0 0.0 999 15 1.71 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Functional impact of dyskinesia Complexity of motor fluctuations
0 695 79.34 274 75.7 0 404 46.12 238 65.8
1 90 10.27 35 9.7 1 291 33.22 85 23.5
2 29 3.31 26 7.2 2 69 7.88 34 9.4
3 46 5.25 19 5.3 3 50 5.71 5 1.4
4 5 0.57 8 2.2 4 46 5.25 0 0.0
999 11 1.26 0 0.0 999 16 1.83 0 0.0
Total 876 100.00 362 100.0 Total 876 100.00 362 100.0
Time spent in the off state Painful off-state dystonia
0 383 43.72 235 64.9 0 680 77.63 309 85.4
1 341 38.93 77 21.3 1 114 13.01 29 8.0
2 106 12.10 38 10.5 2 45 5.14 16 4.4
3 22 2.51 8 2.2 3 13 1.48 8 2.2
4 14 1.60 4 1.1 4 15 1.71 0 0.0
999 10 1.14 0 0.0 999 9 1.03 0 0.0
Total 876 100.00 362 100.0   Total 876 100.00 362 100.0
LLE: left lower extremity, LUE: left upper extremity, MDS-UPDRS: Movement Disorder Society Sponsored Revision of the Unified Parkinson’s Disease 
Rating Scale, RLE: right lower extremity, RUE: right upper extremity.
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Factor analysis
Confirmatory factor analysis
Table 3 lists the CFA models for each part of the MDS-UP-
DRS. The CFI values for all four parts of the Korean MDS-
UPDRS in comparisons with the factor structure of the 
English version were at least 0.91. Since our prespecified cri-
terion was a CFI of at least 0.90, we concluded that the pre-
specified factor structure of the English version of the MDS-
UPDRS was confirmed in the Korean data set. 
Exploratory factor analysis
Our EFA of the Korean data set differed from the EFA of the 
English-language data set in some areas (Fig. 1). From the 
scree plots, we extracted two factors for part I (nonmotor 
aspects of experiences of daily living) (Fig. 1A), three factors 
for part II (motor aspects of experiences of daily living) (Fig. 
1B), seven factors for part III (motor examination) (Fig. 1C), 
and two factors for part IV (motor complications) (Fig. 1D).
The factor structure of part I was consistent with that of 
the English version of the MDS-UPDRS. In part II, “hand-
writing, doing hobbies, and other activities” loaded onto fac-
tor 2 but not factor 1; “tremor” did not load onto any of the 
factors; and “dressing and hygiene” loaded onto factor 2 but 
not factor 3. In part III, “rest tremor amplitude (lip/jaw)” did 
not load onto any of the factors, and nine items loaded onto 
multiple factors. For part IV, the factor structure was consis-
tent with that of the English version of the MDS-UPDRS. We 
evaluated the internal consistency to determine reliability and 
obtained Cronbach’s alpha coefficient for the MDS-UPDRS; 
this was 0.94, which indicated the presence of excellent in-
ternal consistency (Table 4). 
DISCUSSION
This study found that the translated Korean MDS-UPDRS 
shows acceptable validity in factor analyses. The CFA showed 
that all parts of the Korean MDS-UPDRS are consistent with 
all parts of the English MDS-UPDRS, while the EFA extract-
ed the same number of factors from the Korean and English 
versions of the MDS-UPDRS. The MDS proposed a unified 
statistical method for translating the MDS-UPDRS into an-
other language. Compared with previous reports of the MDS-
UPDRS for other languages, the CFI values for all parts of the 
Korean MDS UPDRS exceeded 0.90, indicating significant 
consistency. The Korean MDS-UPDRS therefore shares a com-
mon structure with the English MDS-UPDRS. 
This study was conducted at ten centers across Korea. Most 
of the participants were female, which is similar to previous 
studies involving Asian populations.12,13 This female predom-
inance could be due to several confounding factors, includ-
ing genetic susceptibility, environmental factors, and preven-
tative factors.13
A few mismatches were detected during cognitive pretest-
ing of the Korean translation of the MDS-UPDRS. Dopa-
mine dysregulation syndrome is an unfamiliar term in Kore-
an, with “dysregulation” in particularly not being commonly 
used in Korea. We therefore changed that term to a more nat-
ural expression during cognitive pretesting. Moreover, there 
is only a former term for postural stability in Korean, and so 
we rephrased it into a colloquial expression. 
The distributions for the following items differed between 
the Korean and English versions of the MDS-UPDRS: daytime 
sleepiness, cognitive impairment, hallucination, and depres-
sive mood in part I; turning in and getting out of bed, speech, 
dressing, handwriting, walking/balance, and freezing in part 
II; toe tapping, leg agility, and postural stability in part III; and 
complexity of motor fluctuations, time spent in the off state, 
time spent with dyskinesia, and functional impact of dyski-
nesia in part IV. The difference in the “turning in and getting 
out of bed” item may have been caused by cultural differences. 
Most Koreans sleep on a Korean-style mattress on the floor 
rather than on a bed , and so sleeping on a Korean-style mat-
tress makes getting out of bed more difficult. The differences 
in other items may have been caused by language differenc-
es. The terms “tapping,” “agility,” “complexity,” “fluctuation,” 
“off state,” “postural stability,” and “dyskinesia” are more diffi-
cult to translate into Korean and are not easy to understand. 
Several items in part I, including cognitive impairment, hal-
lucination, and depressive mood, are usually rated by care-
givers rather than by the patients themselves. Caregivers can 
be easily affected by the medical environment or healthcare 
system in their own country. “Time spent with dyskinesia” and 
Table 3. Confirmatory factor analysis model fit
Part I: nonmotor aspects of experiences of daily living (two-factor model)*
Korean MDS-UPDRS CFI=0.91, RMSEA=0.08 (356 patients)
English MDS-UPDRS CFI=0.96, RMSEA=0.06 (849 patients)
Part II: motor aspects of experiences of daily living (three-factor model)
Korean MDS-UPDRS CFI=0.96, RMSEA=0.14 (359 patients)
English MDS-UPDRS CFI=0.97, RMSEA=0.09 (851 patients)
Part III: motor examination (seven-factor model)
Korean MDS-UPDRS CFI=0.92, RMSEA=0.09 (360 patients)
English MDS-UPDRS CFI=0.95, RMSEA=0.07 (801 patients)
Part IV: motor complications (two-factor model)
Korean MDS-UPDRS CFI=0.99, RMSEA=0.11 (362 patients)
English MDS-UPDRS CFI=1.00, RMSEA=0.04 (848 patients)
*Dopamine dysregulation syndrome was not included in this analysis 
since it did not load onto any factor. 
CFI: comparative fit index, MDS-UPDRS: Movement Disorder Society 
Sponsored Revision of the Unified Parkinson’s Disease Rating Scale, 
RMSEA: root-mean-square error approximation.
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Fig. 1. Scree plot of the Korean and English Movement Disorder Society Sponsored Revision of the Unified Parkinson’s Disease Rating Scale, from 
which two factors were extracted for part I (nonmotor aspects of experiences of daily living) (A), three factors for part II (motor aspects of experi-
ences of daily living) (B), seven factors for part III (motor examination) (C), and two factors for part IV (motor complications) (D).
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“time spent in the off state” are usually obtained from patients, 
which can cause an informative bias because many patients 
with PD have cognitive dysfunction during the motor-com-
plications stage. It is particularly interesting that these differ-
ences were not similar to those of the Japanese validation 
study, which indicates that differences in culture and language 
between countries should always be considered when trans-
lating the MDS-UPDRS. However, the discrepancies did not 
affect the validation of the Korean MDS-UPDRS in the pres-
ent study. 
The good fitness of the model was indicated by the CFI val-
ues exceeding 0.90 for all parts of the Korean MDS-UPDRS. 
The RMSEA values for parts II and IV were relatively high, 
but we decided to use the CFI to evaluate statistical signifi-
cance. Variability from sample to sample was expected during 
the EFA, and we identified isolated item differences in the fac-
tor structures of the Korean and English versions of the MDS-
UPDRS. Several items had cross-loading for multiple factors 
in the Korean scale, which might have been due to inherent 
differences between the Korean and English languages as well 
as cultural differences. However, scree plots of the Korean ver-
sion revealed that two, three, seven, and two factors in parts I, 
II, III, and IV, respectively, were similar to those for the Eng-
lish version (Fig. 1). Both the EFA and CFA demonstrated that 
the Korean and English versions of the MDS-UPDRS share a 
common structure. The Korean MDS-UPDRS is available at 
the official MDS webpage (https://www.movementdisorders.
org/MDS/MDS-Rating-Scales/MDS-Unified-Parkinsons-
Disease-Rating-Scale-MDS-UPDRS.htm).
The high CFI values (all >0.90) obtained in the CFA for all 
four parts of the Korean MDS-UPDRS indicate that the over-
all factor structure of the Korean version of the MDS-UPDRS 
is consistent with that of the English version. Moreover, the 
EFA also showed that the number of factors was the same in 
each part of the Korean and English versions. Cronbach’s al-
pha coefficient indicated excellent internal consistency. How-
ever, future studies of the interrater and intrarater reliabilities 
are necessary. The version validated in the present study can 
be designated as the official Korean version of the MDS-UP-
DRS.
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